|Dr. Xue-Song Liu obtained his bachelor degree from School of Life Science, Wuhan University in 2002. He received his doctor degree from Institute of Health Sciences, Shanghai Institutes for Biological Sciences in 2007. He did his postdoc research in Medical School and School of Public Health of Harvard University from 2008 to 2015. Dr. Liu joined School of Life Science and Technology of ShanghaiTech University as an assistant professor, PI since June 2015.|
|Cancers are majorly caused by mutations or aberrant expression of cancer genes. We are interested in the molecular and genetic study of human cancer, and will use multiple approaches, including biochemistry, cell biology, bioinformatics and mouse model to study the genomics of human cancer. We will identify and study the function of novel cancer genes, particularly those genes that play roles in regulating chromatin structure and RNA biogenesis. We are also interested in therapeutically targeting cancer cells with defined common genetic alterations.|
1. Wang SX*, Jia MM*, He ZK, Liu XS#. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 2018 Apr 26. doi: 10.1038/s41388-018-0245-9 (* first author; # correspondence)
2. Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, Diolombi MS, Breitkopf SB, Teruya-Feldstein J, Signoretti S, Bronson RT, Asara JM, Castillo-Martin M, Cordon-Cardo C, Pandolfi PP. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 2018 Feb;50(2):206-218.
3. Liu XS, Liu Z, Gerarduzzi C, Choi DE, Ganapathy S, Pandolfi PP, Yuan ZM. Somatic human ZBTB7A zinc finger mutations promote cancer progression. Oncogene. 2015 Oct 12. doi: 10.1038/onc.2015.371.
4. Liu XS*, Chandramouly G, Rass E, Guan Y, Wang G, Hobbs RM, Rajendran A, Xie A, Shah JV, Davis AJ, Scully R, Lunardi A*, Pandolfi PP. LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair. Nature Communications. 2015 Oct 8; 6:8325. doi: 10.1038/ncomms9325. (* co-first author)
5. Liu XS, Genet MD, Haines JE, Mehanna EK, Wu S, Chen HI, Chen Y, Qureshi AA, Han J, Chen X, Fisher DE, Pandolfi PP, Yuan ZM. ZBTB7A suppresses melanoma metastasis by transcriptionally repressing MCAM. Mol Cancer Res. 2015, 13(8):1206-17.
6. Liu XS, Little JB, Yuan ZM. Glycolytic metabolism influences global chromatin structure. Oncotarget. 2015, 6(6):4214-25.
7. Liu XS, Haines JE, Mehanna EK, Genet MD, Ben-Sahra I, Asara JM, Manning BD, Yuan ZM. ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis. Genes Dev. 2014, 28(17):1917-28. (Highlighted in Nature Reviews Cancer: Isabel Lokody, Nature Reviews Cancer, 14, 649 (2014))
8. González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014, 4(8):896-904.
9. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. 2013, 45(7):739-46.
10. Zhang HX, Liu ZX, Sun YP, Zhu J, Lu SY, Liu XS, Huang QH, Xie YY, Zhu HB, Dang SY, Chen HF, Zheng GY, Li YX, Kuang Y, Fei J, Chen SJ, Chen Z, Wang ZG. Rig-I regulates NF-κB activity through binding to Nf-κb1 3'-UTR mRNA. Proc Natl Acad Sci U S A. 2013, 110(16):6459-64.
11. Liu XS*, Zhao XD*, Wang X*, Yao YX, Zhang LL, Shu RZ, Ren WH, Huang Y, Huang L, Gu MM, Kuang Y, Wang L, Lu SY, Chi J, Fen JS, Wang YF, Fei J, Dai W, Wang ZG. Germinal Cell Aplasia in Kif18aMutant Male Mice Due to Impaired Chromosome Congression and Dysregulated BubR1 and CENP-E. Genes Cancer. 2010, 1(1):26-39. (* co-first author) (Highlighted as cover story)
12. Shu RZ, Zhang F, Liu XS, Li CL, Wang L, Tai YL, Wu XL, Yang X, Liao XD, Jin Y, Gu MM, Huang L, Pang XF, Wang ZG. Target deletion of the cytoskeleton-associated protein palladin does not impair neurite outgrowth in mice. PLoS One. 2009, 4(9):e6916.
13. Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, Xu JQ, Cui B, Wang L, Lu SY, Chen XY, Zhang HG, Huang W, Yuan WT, Yang JM, Gu Q, Fei J, Chen Z, Yuan ZM, Wang ZG. Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene. Am J Hum Genet. 2009, 85(1):53-63.
14. Wang Y, Zhang HX, Sun YP, Liu ZX, Liu XS, Wang L, Lu SY, Kong H, Liu QL, Li XH, Lu ZY, Chen SJ, Chen Z, Bao SS, Dai W, Wang ZG. Rig-I-/- mice develop colitis associated with downregulation of G alpha i2. Cell Res. 2007, 17(10):858-68.
15. Liu XS, Li XH, Wang Y, Shu RZ, Wang L, Lu SY, Kong H, Jin YE, Zhang LJ, Fei J, Chen SJ, Chen Z, Gu MM, Lu ZY, Wang ZG. Disruption of palladin leads to defects in definitive erythropoiesis by interfering with erythroblastic island formation in mouse fetal liver. Blood. 2007, 110(3):870-76.
16. Liu XS, Luo HJ, Yang H, Wang L, Kong H, Jin YE, Wang F, Gu MM, Chen Z, Lu ZY, Wang ZG. Palladin regulates cell and extracellular matrix interaction through maintaining normal actin cytoskeleton architecture and stabilizing beta1-integrin. J Cell Biochem. 2007, 100(5):1288-300.
17. Luo H*, Liu X*, Wang F, Huang Q, Shen S, Wang L, Xu G, Sun X, Kong H, Gu M, Chen S, Chen Z, Wang Z. Disruption of palladin results in neural tube closure defects in mice. Mol Cell Neurosci. 2005, 29(4):507-15. (* co-first author)